Skip to main content
Erschienen in: Neurological Sciences 9/2018

01.09.2018 | Original Article

Rate of augmentation and risk factors with long-term follow-up in Japanese patients with restless legs syndrome

verfasst von: Kosuke Tanioka, Mutsumi Okura, Manami Inoue, Koh-Ichiro Taniguchi, Mitsutaka Taniguchi, Toshiaki Hamano, Naoko Tachibana

Erschienen in: Neurological Sciences | Ausgabe 9/2018

Einloggen, um Zugang zu erhalten

Abstract

Objectives

Preventing augmentation is the critical clinical issue for RLS treatment. As for augmentation in Asian RLS patients, there have been only four studies and the follow-up durations of these studies were not long. We investigated Japanese RLS patients with longer duration of treatment in a clinical setting.

Methods

This study is a retrospective assessment of 42 RLS patients with follow-up durations of longer than 18 months (78.4 ± 29.2, range 19–139) at two urban sleep centers in Osaka, Japan from May 2004 to April 2014.

Results

The mean age of first visit was 63.5 ± 14.1 years old and the estimated age of RLS onset was 47.9 ± 16.5 years old. Twenty-eight out of 42 patients were female. At initial evaluation, the mean International Restless Legs Scale score (IRLS score) was 22.0 ± 5.9. Thirty-one of 42 had already visited other clinics before coming to our sleep centers, and the number of clinics visited was 1.3 ± 0.6. Augmentation developed in two patients (4.8%), and the dosage of dopamine equivalent in patients with and without augmentation was 12.5 and 18.8 mg vs. 15.8 ± 17.7 mg. In the two RLS patients with augmentation, ferritin was 113.1 and 114.1 ng/mL, respectively, and the number of clinics before coming to our sleep centers was both three.

Conclusions

The augmentation rate of Japanese RLS patients from our study is low compared with previous Western and Asian studies. It might be attributable to racial difference, lower dosage of dopaminergic treatment, and the level of ferritin.
Literatur
1.
Zurück zum Zitat Winkelman JW, Armstrong MJ, Allen RP, Chaudhuri KR, Ondo WG, Trenkwalder C, Zee PC, Gronseth GS, Gloss D, Zesiewicz T (2016) Practice guideline summary: treatment of restless legs syndrome in adults: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 87(24):2585–2593CrossRefPubMedPubMedCentral Winkelman JW, Armstrong MJ, Allen RP, Chaudhuri KR, Ondo WG, Trenkwalder C, Zee PC, Gronseth GS, Gloss D, Zesiewicz T (2016) Practice guideline summary: treatment of restless legs syndrome in adults: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 87(24):2585–2593CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat García-Borreguero D, Silber MH, Winkelman JW, Högl B, Bainbridge J, Buchfuhrer M, Hadjigeorgiou G, Inoue Y, Manconi M, Oertel W, Ondo W, Winkelmann J, Allen RP (2016) Guidelines for the first-line treatment of restless legs syndrome/Willis–Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. Sleep Med 21:1–11CrossRefPubMed García-Borreguero D, Silber MH, Winkelman JW, Högl B, Bainbridge J, Buchfuhrer M, Hadjigeorgiou G, Inoue Y, Manconi M, Oertel W, Ondo W, Winkelmann J, Allen RP (2016) Guidelines for the first-line treatment of restless legs syndrome/Willis–Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. Sleep Med 21:1–11CrossRefPubMed
3.
Zurück zum Zitat García-Borreguero D, Allen RP, Kohnen R, Högl B, Trenkwalder C, Oertel W, Hening WA, Paulus W, Rye D, Walters A, Winkelmann J, on behalf of the International Restless Legs Syndrome Study Group (IRLSSG) (2007) Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine—International Restless Legs Syndrome Study Group Consensus Conference at the Max Planck Institute. Sleep Med 8(5):520–530CrossRefPubMed García-Borreguero D, Allen RP, Kohnen R, Högl B, Trenkwalder C, Oertel W, Hening WA, Paulus W, Rye D, Walters A, Winkelmann J, on behalf of the International Restless Legs Syndrome Study Group (IRLSSG) (2007) Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine—International Restless Legs Syndrome Study Group Consensus Conference at the Max Planck Institute. Sleep Med 8(5):520–530CrossRefPubMed
4.
Zurück zum Zitat Allen RP, Ondo WG, Ball E, Calloway MO, Manjunath R, Higbie RL, Lee MR, Nisbet PA (2011) Restless legs syndrome (RLS) augmentation associated with dopamine agonist and levodopa usage in a community sample. Sleep Med 12(5):431–439CrossRefPubMed Allen RP, Ondo WG, Ball E, Calloway MO, Manjunath R, Higbie RL, Lee MR, Nisbet PA (2011) Restless legs syndrome (RLS) augmentation associated with dopamine agonist and levodopa usage in a community sample. Sleep Med 12(5):431–439CrossRefPubMed
5.
Zurück zum Zitat Ondo WG, Romanyshyn J, Vuong KD, Lai D (2004) Long-term treatment of restless legs syndrome with dopamine agonists. Arch Neurol 61(9):1393–1397CrossRefPubMed Ondo WG, Romanyshyn J, Vuong KD, Lai D (2004) Long-term treatment of restless legs syndrome with dopamine agonists. Arch Neurol 61(9):1393–1397CrossRefPubMed
6.
Zurück zum Zitat Winkelman JW, Johnston L (2004) Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS). Sleep Med 5(1):9–14CrossRefPubMed Winkelman JW, Johnston L (2004) Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS). Sleep Med 5(1):9–14CrossRefPubMed
7.
Zurück zum Zitat Silber MH, Shepard JW, Wisbey JA (1997) Pergolide in the management of restless legs syndrome: an extended study. Sleep 20(10):878–882CrossRefPubMed Silber MH, Shepard JW, Wisbey JA (1997) Pergolide in the management of restless legs syndrome: an extended study. Sleep 20(10):878–882CrossRefPubMed
8.
Zurück zum Zitat Silber MH, Girish M, Izurieta R (2003) Pramipexole in the management of restless legs syndrome: an extended study. Sleep 26(7):819–821CrossRefPubMed Silber MH, Girish M, Izurieta R (2003) Pramipexole in the management of restless legs syndrome: an extended study. Sleep 26(7):819–821CrossRefPubMed
9.
Zurück zum Zitat Silver N, Allen RP, Senerth J, Earley CJ (2011) A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome. Sleep Med 12(5):440–444CrossRefPubMed Silver N, Allen RP, Senerth J, Earley CJ (2011) A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome. Sleep Med 12(5):440–444CrossRefPubMed
10.
Zurück zum Zitat Lipford MC, Silber MH (2012) Long-term use of pramipexole in the management of restless legs syndrome. Sleep Med 13(10):1280–1285CrossRefPubMed Lipford MC, Silber MH (2012) Long-term use of pramipexole in the management of restless legs syndrome. Sleep Med 13(10):1280–1285CrossRefPubMed
11.
Zurück zum Zitat Frauscher B, Gschliesser V, Brandauer E, El-Demerdash E, Kaneider M, Rücker L, Poewe W, Högl B (2009) The severity range of restless legs syndrome (RLS) and augmentation in a prospective patient cohort: association with ferritin levels. Sleep Med 10(6):611–615CrossRefPubMed Frauscher B, Gschliesser V, Brandauer E, El-Demerdash E, Kaneider M, Rücker L, Poewe W, Högl B (2009) The severity range of restless legs syndrome (RLS) and augmentation in a prospective patient cohort: association with ferritin levels. Sleep Med 10(6):611–615CrossRefPubMed
12.
Zurück zum Zitat Jeon J-Y, Moon H-J, Song ML, Lee HB, Cho YW (2015) Augmentation in restless legs syndrome patients in Korea. Sleep Breath 19(2):523–529CrossRefPubMed Jeon J-Y, Moon H-J, Song ML, Lee HB, Cho YW (2015) Augmentation in restless legs syndrome patients in Korea. Sleep Breath 19(2):523–529CrossRefPubMed
13.
Zurück zum Zitat Inoue Y, Hirata K, Hayashida K, Hattori N, Tomida T, García-Borreguero D (2013) Efficacy, safety and risk of augmentation of rotigotine for treating restless legs syndrome. Prog Neuro-Psychopharmacol Biol Psychiatry 40:326–333CrossRef Inoue Y, Hirata K, Hayashida K, Hattori N, Tomida T, García-Borreguero D (2013) Efficacy, safety and risk of augmentation of rotigotine for treating restless legs syndrome. Prog Neuro-Psychopharmacol Biol Psychiatry 40:326–333CrossRef
14.
Zurück zum Zitat Takahashi M, Nishida S, Nakamura M, Kobayashi M, Matsui K, Ito E, Usui A, Inoue Y (2017) Restless legs syndrome augmentation among Japanese patients receiving pramipexole therapy: rate and risk factors in a retrospective study. PLoS One 12(3):e0173535CrossRefPubMedPubMedCentral Takahashi M, Nishida S, Nakamura M, Kobayashi M, Matsui K, Ito E, Usui A, Inoue Y (2017) Restless legs syndrome augmentation among Japanese patients receiving pramipexole therapy: rate and risk factors in a retrospective study. PLoS One 12(3):e0173535CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Allen RP, Picchietti DL, García-Borreguero D, Ondo WG, Walters AS, Winkelman JW, Zuccconi M, Ferri R, Trenkwalder C, Lee HB, on behalf of the International Restless Legs Study Group (2014) Restless legs syndrome/Willis–Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria—history, rationale, description, and significance. Sleep Med 15(8):860–873CrossRefPubMed Allen RP, Picchietti DL, García-Borreguero D, Ondo WG, Walters AS, Winkelman JW, Zuccconi M, Ferri R, Trenkwalder C, Lee HB, on behalf of the International Restless Legs Study Group (2014) Restless legs syndrome/Willis–Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria—history, rationale, description, and significance. Sleep Med 15(8):860–873CrossRefPubMed
16.
Zurück zum Zitat Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25(15):2649–2653CrossRefPubMed Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25(15):2649–2653CrossRefPubMed
17.
Zurück zum Zitat Allen RP, Earley CJ (1996) Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep 19(3):205–213CrossRefPubMed Allen RP, Earley CJ (1996) Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep 19(3):205–213CrossRefPubMed
18.
Zurück zum Zitat Allen RP, Chen C, García-Borreguero D, Polo O, DuBrava S, Miceli J, Knapp L, Winkelman JW (2014) Comparison of pregabalin with pramipexole for restless legs syndrome. N Engl J Med 370(7):621–631CrossRefPubMed Allen RP, Chen C, García-Borreguero D, Polo O, DuBrava S, Miceli J, Knapp L, Winkelman JW (2014) Comparison of pregabalin with pramipexole for restless legs syndrome. N Engl J Med 370(7):621–631CrossRefPubMed
19.
Zurück zum Zitat Trenkwalder C, Beneš H, Grote L, Happe S, Högl B, Mathis J, Saletu-Zyhlarz GM, Kohnen R, on behalf of the CALDIR study group (2007) Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: results from a multi-center, randomized, active controlled trial. Mov Disord 22(5):696–703CrossRefPubMed Trenkwalder C, Beneš H, Grote L, Happe S, Högl B, Mathis J, Saletu-Zyhlarz GM, Kohnen R, on behalf of the CALDIR study group (2007) Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: results from a multi-center, randomized, active controlled trial. Mov Disord 22(5):696–703CrossRefPubMed
20.
Zurück zum Zitat García-Borreguero D, Ferini-Strambi L, Kohnen R (2008) Augmentation in the therapy of restless legs syndrome with transdermal rotigotine: a retrospective systematic analysis of two large double-blind 6-month trials. Eur J Neurol 15(Suppl.3):110 García-Borreguero D, Ferini-Strambi L, Kohnen R (2008) Augmentation in the therapy of restless legs syndrome with transdermal rotigotine: a retrospective systematic analysis of two large double-blind 6-month trials. Eur J Neurol 15(Suppl.3):110
21.
Zurück zum Zitat Högl B, García-Borreguero D, Trenkwalder C, Ferini-Strambi L, Hening W, Poewe W, Brenner SS, Fraessdorf M, Busse M, Albrecht S, Allen RP (2011) Efficacy and augmentation during 6 months of double-blind pramipexole for restless legs syndrome. Sleep Med 12(4):351–360CrossRefPubMed Högl B, García-Borreguero D, Trenkwalder C, Ferini-Strambi L, Hening W, Poewe W, Brenner SS, Fraessdorf M, Busse M, Albrecht S, Allen RP (2011) Efficacy and augmentation during 6 months of double-blind pramipexole for restless legs syndrome. Sleep Med 12(4):351–360CrossRefPubMed
22.
Zurück zum Zitat Trenkwalder C, Beneš H, Poewe W, Oertel WH, García-Borreguero D, Al W, Ferini-Strambi L, Montagna P, Odin P, Stiasny-Kolster K, Högl B, Chaudhuri KR, Partinen M, Schollmayer E, Kohnen R, for the SP 790 Study Group (2008) Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 7(7):595–604CrossRefPubMed Trenkwalder C, Beneš H, Poewe W, Oertel WH, García-Borreguero D, Al W, Ferini-Strambi L, Montagna P, Odin P, Stiasny-Kolster K, Högl B, Chaudhuri KR, Partinen M, Schollmayer E, Kohnen R, for the SP 790 Study Group (2008) Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 7(7):595–604CrossRefPubMed
23.
Zurück zum Zitat Beneš H, Heinrich CR, Ueberall MA, Kohnen R (2004) Long-term safety and efficacy of cabergoline for the treatment of idiopathic restless legs syndrome: results from an open-label 6-month clinical trial. Sleep 27(4):674–682CrossRefPubMed Beneš H, Heinrich CR, Ueberall MA, Kohnen R (2004) Long-term safety and efficacy of cabergoline for the treatment of idiopathic restless legs syndrome: results from an open-label 6-month clinical trial. Sleep 27(4):674–682CrossRefPubMed
24.
Zurück zum Zitat Ferini-Strambi L (2002) Restless legs syndrome augmentation and pramipexole treatment. Sleep Med 3(Suppl):S23–S25CrossRefPubMed Ferini-Strambi L (2002) Restless legs syndrome augmentation and pramipexole treatment. Sleep Med 3(Suppl):S23–S25CrossRefPubMed
25.
Zurück zum Zitat Högl B, García-Borreguero D, Kohnen R, Ferini-Strambi L, Hadjigeorgiou G, Hornyak M, Weerd A, Happe S, Stiasny-Kolster K, Gschliesser V, Egatz R, Frauscher B, Benes H, Trenkwalder C, Hening WA, Allen RP (2010) Progressive development of augmentation during long-term treatment with levodopa in restless legs syndrome: results of a prospective multi-center study. J Neurol 257(2):230–237CrossRefPubMed Högl B, García-Borreguero D, Kohnen R, Ferini-Strambi L, Hadjigeorgiou G, Hornyak M, Weerd A, Happe S, Stiasny-Kolster K, Gschliesser V, Egatz R, Frauscher B, Benes H, Trenkwalder C, Hening WA, Allen RP (2010) Progressive development of augmentation during long-term treatment with levodopa in restless legs syndrome: results of a prospective multi-center study. J Neurol 257(2):230–237CrossRefPubMed
26.
Zurück zum Zitat Stiasny-Kolster K, Beneš H, Peglau I, Hornyak M, Wessel K, Emser W, Leroux M, Kohnen R, Oertel WH (2004) Effective cabergoline treatment in idiopathic restless legs syndrome. Neurology 63(12):2272–2279CrossRefPubMed Stiasny-Kolster K, Beneš H, Peglau I, Hornyak M, Wessel K, Emser W, Leroux M, Kohnen R, Oertel WH (2004) Effective cabergoline treatment in idiopathic restless legs syndrome. Neurology 63(12):2272–2279CrossRefPubMed
27.
Zurück zum Zitat Beneš H, García-Borreguero D, Allen RP (2009) Augmentation in long-term therapy of the restless legs syndrome with transdermal rotigotine—a retrospective systematic analysis of two large open-label 1-year trials. Mov Disord 24:S438 Beneš H, García-Borreguero D, Allen RP (2009) Augmentation in long-term therapy of the restless legs syndrome with transdermal rotigotine—a retrospective systematic analysis of two large open-label 1-year trials. Mov Disord 24:S438
28.
Zurück zum Zitat Beneš H, García-Borreguero D, Ferini-Strambi L, Schollmayer E, Fichtner A, Kohnen R (2012) Augmentation in the treatment of restless legs syndrome with transdermal rotigotine. Sleep Med 13(6):589–597CrossRefPubMed Beneš H, García-Borreguero D, Ferini-Strambi L, Schollmayer E, Fichtner A, Kohnen R (2012) Augmentation in the treatment of restless legs syndrome with transdermal rotigotine. Sleep Med 13(6):589–597CrossRefPubMed
29.
Zurück zum Zitat García-Borreguero D, Grunstein R, Sridhar G, Dreykluft T, Montagna P, Dom R, Lainey E, Moorat A, Roberts J (2007) A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome. Sleep Med 8(7):742–752CrossRefPubMed García-Borreguero D, Grunstein R, Sridhar G, Dreykluft T, Montagna P, Dom R, Lainey E, Moorat A, Roberts J (2007) A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome. Sleep Med 8(7):742–752CrossRefPubMed
30.
Zurück zum Zitat García-Borreguero D, Högl B, Ferini-Strambi L, Winkelman J, Hill-Zabala C, Asgharian A, Allen RP (2012) Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis-Ekbom disease): results from a prospective, multicenter study over 66 weeks. Mov Disord 27(2):277–283CrossRefPubMed García-Borreguero D, Högl B, Ferini-Strambi L, Winkelman J, Hill-Zabala C, Asgharian A, Allen RP (2012) Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis-Ekbom disease): results from a prospective, multicenter study over 66 weeks. Mov Disord 27(2):277–283CrossRefPubMed
31.
Zurück zum Zitat García-Borreguero D, Kohnen R, Högl B, Ferini-Strambi L, Hadjigeorgiou GM, Hornyak M, Weerd A, Happe S, Stiasny-Kolster K, Gschliesser V, Egatz R, Cabrero B, Frauscher B, Trenkwalder C, Hening WA, Allen RP (2007) Validation of the Augmentation Severity Rating Scale (ASRS): a multicentric, prospective study with levodopa on restless legs syndrome. Sleep Med 8(5):455–463CrossRefPubMed García-Borreguero D, Kohnen R, Högl B, Ferini-Strambi L, Hadjigeorgiou GM, Hornyak M, Weerd A, Happe S, Stiasny-Kolster K, Gschliesser V, Egatz R, Cabrero B, Frauscher B, Trenkwalder C, Hening WA, Allen RP (2007) Validation of the Augmentation Severity Rating Scale (ASRS): a multicentric, prospective study with levodopa on restless legs syndrome. Sleep Med 8(5):455–463CrossRefPubMed
32.
Zurück zum Zitat Oertel W, Trenkwalder C, Beneš H, Ferini-Strambi L, Högl B, Poewe W, Stiasny-Kolster K, Fichtner A, Schollmayer E, Kohnen R, García-Borreguero D, on behalf of the SP710 study group (2011) Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study. Lancet Neurol 10(8):710–720CrossRefPubMed Oertel W, Trenkwalder C, Beneš H, Ferini-Strambi L, Högl B, Poewe W, Stiasny-Kolster K, Fichtner A, Schollmayer E, Kohnen R, García-Borreguero D, on behalf of the SP710 study group (2011) Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study. Lancet Neurol 10(8):710–720CrossRefPubMed
33.
Zurück zum Zitat Stiasny-Kolster K, Wetter TC, Winkelmann JW, Brandenburg U, Penzel T, Rubin M, Hundemer HP, Oertel WH, Trenkwalder C (2001) Long-term effects of pergolide in the treatment of restless legs syndrome. Neurology 56(10):1399–1402CrossRef Stiasny-Kolster K, Wetter TC, Winkelmann JW, Brandenburg U, Penzel T, Rubin M, Hundemer HP, Oertel WH, Trenkwalder C (2001) Long-term effects of pergolide in the treatment of restless legs syndrome. Neurology 56(10):1399–1402CrossRef
34.
Zurück zum Zitat Inoue Y, Kuroda K, Hirata K, Uchimura N, Kagimura T, Shimizu T (2010) Long-term open-label study of pramipexole in patients with primary restless legs syndrome. J Neurol Sci 294(1):62–66CrossRefPubMed Inoue Y, Kuroda K, Hirata K, Uchimura N, Kagimura T, Shimizu T (2010) Long-term open-label study of pramipexole in patients with primary restless legs syndrome. J Neurol Sci 294(1):62–66CrossRefPubMed
35.
Metadaten
Titel
Rate of augmentation and risk factors with long-term follow-up in Japanese patients with restless legs syndrome
verfasst von
Kosuke Tanioka
Mutsumi Okura
Manami Inoue
Koh-Ichiro Taniguchi
Mitsutaka Taniguchi
Toshiaki Hamano
Naoko Tachibana
Publikationsdatum
01.09.2018
Verlag
Springer Milan
Erschienen in
Neurological Sciences / Ausgabe 9/2018
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-018-3456-5

Weitere Artikel der Ausgabe 9/2018

Neurological Sciences 9/2018 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.